Reckitt Benckiser Group has upgraded its 2025 outlook and is now aiming for like-for-like net revenue growth above 4 percent in Core Reckitt. This compares with the previous target range of 3 percent to 4 percent.<\/p>\n The company has launched a share repurchase program, authorizing up to \u00a31 billion of shares to be bought back and cancelled over the next 12 months.<\/p>\n An interim 2025 dividend of 84.4 pence has been recommended. This is an increase from the 80.4 pence paid in the first half of 2024, with the next payment planned for September 2025.<\/p>\n New data from the Guaifenesin Assessment of Satisfaction for Patients (GASP) Study has been released, indicating sustained symptom improvement and high patient satisfaction with long-term use of Mucinex ER for chronic bronchitis management.<\/p>\n Story Continues <\/p>\n How This Changes the Fair Value For Reckitt Benckiser Group <\/p>\n Fair Value: Remains unchanged at \u00a360.33 per share. This indicates no material reassessment of intrinsic value.<\/p>\n Discount Rate: Holds steady at 6.82%, reflecting consistent expectations regarding risk and return.<\/p>\n Revenue Growth: Stable at 3.21% per year, with no revision to future topline growth forecasts.<\/p>\n Net Profit Margin: Unchanged at 17.11%. This suggests analysts see profitability remaining at similar levels.<\/p>\n Future P\/E: Remains at 18.37x, demonstrating no shift in market valuation multiples assigned to forward earnings.<\/p>\n \ud83d\udd14 Never Miss an Update: Follow The Narrative <\/p>\n A Narrative is your personalized lens on a company’s future, linking its real-world story to financial forecasts and fair value estimates. Narratives help investors understand not just what the numbers say, but why. They blend insight with clear projections and let you compare Fair Value to the current Price with confidence. On Simply Wall St, Narratives are accessible to all and updated dynamically as new information emerges, empowering you to make smarter, more timely investment decisions.<\/p>\n Curious what the latest Narrative spells out for Reckitt Benckiser Group? Read the full analyst commentary here<\/a> and stay ahead on:<\/p>\n How expansion in emerging markets and ongoing innovation could propel Reckitt Benckiser\u2019s revenue growth and margins well above industry averages<\/p>\n Why strategic cost reductions and portfolio optimization might strengthen key brands and earnings resilience even in the face of global uncertainty<\/p>\n Which legal, competitive, and execution risks could impact future profits, and how the consensus view translates those risks into a fair value assessment<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include RKT.L<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Reckitt Benckiser Group\u2019s stock has attracted renewed attention following recent updates to analysts\u2019 price targets. Some experts have…\n","protected":false},"author":2,"featured_media":42314,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[21355],"tags":[21534,1839,21126,22715,21388,21376,1854],"class_list":["post-44722","post","type-post","status-publish","format-standard","has-post-thumbnail","category-reckitt-benckiser","tag-core-reckitt","tag-fair-value","tag-james-edwardes-jones","tag-market-valuation","tag-price-targets","tag-reckitt-benckiser","tag-revenue-growth"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116614803572336015","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/44722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=44722"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/44722\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/42314"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=44722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=44722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=44722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"LSE:RKT](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/05\/0e888bb83f1d22b157edd202962b2d28.png\")
<\/a> LSE:RKT Community Fair Values as at Oct 2025 What’s in the News <\/p>\n